ASCIA HAE Position Paper and Management Plan

The following ASCIA Hereditary Angioedema (HAE) documents have been updated in 2020 to be consistent with international guidelines and include new treatment options.  These changes are explained in an ASCIA Webinar about  HAE that was presented on 30 March 2020. An update to page 12 has been made in July 2020, in response to the new product registration in New Zealand for prophylaxis of HAE attacks.
ASCIA HAE Working Party members are listed at 

ASCIA Hereditary Angioedema Position Paper 2020  ASCIA Management Plan HAE 2020  ASCIA HAE Case Peer Review Form 2020

For information regarding supply of danazol in Australia please refer to

HAE Australasia is a support organisation for people with HAE and their carers in Australia and New Zealand.  For more information visit 

For information about how ASCIA information for health professionals is developed go to:

Content updated July 2020